Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.36 |
| ▸ | TDO2 | P48775 | 13/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 3/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.34 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803228 | 0.80 | IDO1 (0.38) | IDO1TDO2HTTSCN1ASCN2A | |
| SCHEMBL2839765 | 0.79 | HTT (0.41) | IDO1TDO2HTTSCN1ASCN2A | |
| SCHEMBL1065153 | 0.77 | IDO1 (0.40) | IDO1TDO2HTTSCN1ASCN2A | |
| SCHEMBL7716632 | 0.74 | HTT (0.41) | IDO1TDO2HTTSCN1ASCN2A | |
| SCHEMBL17520022 | 0.69 | TAAR1 (0.35) | IDO1TDO2LMNAADRA2ACYP2D6 | |
| SCHEMBL7718706 | 0.69 | IDO1 (0.42) | IDO1TDO2HTTSCN1ASCN2A | |
| SCHEMBL29980071 | 0.69 | ADRA2A (0.42) | LMNAADRA2ACYP2D6ADRA2BHTR6 | |
| SCHEMBL9232899 | 0.69 | ADRA2A (0.42) | LMNAADRA2ACYP2D6ADRA2BHTR6 | |
| SCHEMBL2843916 | 0.68 | PTGS2 (0.42) | SMN1; SMN2 | |
| SCHEMBL3629865 | 0.68 | KDM4E (0.33) | LMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024930-A1 | METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULE | TORAY INDUSTRIES, INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-9988415-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| EP-2801617-B1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE | BONAC CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160376589-A1 | micro-RNA INHIBITOR | BONAC CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9528111-B2 | Single-stranded nucleic acid molecule having amino acid backbone | BONAC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9481702-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-9404108-B2 | Micro-RMA inhibitor | BONAC CORPORATION (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2016-06-23 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150073124-A1 | micro-RNA INHIBITOR | BONAC CORPORATION (JP) | 2015-03-12 | — | — | US | disclosed |
| US-20140329886-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE | BONAC CORPORATION (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171486-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-8691782-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329886-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE | ZFX, YBX1, SRRT | IDO1 761/4885TDO2 3090/4885HTT 3201/4885 |
| US-20150073124-A1 | micro-RNA INHIBITOR | AGO2, SLIRP, MSI2 | IDO1 3231/4885TDO2 4432/4885HTT 2160/4885 |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | NSUN2, CTDSP1, RNGTT | IDO1 1172/4885TDO2 3251/4885HTT 3951/4885 |
| US-20160176810-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | IDO1 4838/4885TDO2 2597/4885HTT 2210/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | IDO1 1172/4885TDO2 3251/4885HTT 3951/4885 |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | IDO1 4838/4885TDO2 2597/4885HTT 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.